“In the care home, I really wanted Jelly Drops to tackle dehydration and also to be really fun and engaging and sort of a social tool in the care home as well,” Hornby said in a video interview with ...

Published in the April 2018 issue of the Journal of Alzheimer’s Disease , trial results showed improvement in memory and brain health for all who used the formula. Caregivers also reported that AD ...

There were also incidents when my mother spoke harshly to a stranger, and I gently told her that she needed to remember to be kind. She always accepted that information and reverted to her core ...

The company recently announced results from two Phase 3 trials testing AXS-05. One study, ACCORD-2, hit its main goal while the other, ADVANCE-2, didn’t. Axsome said it will use data from these trials ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

With this approval, Aduhelm becomes the first disease-modifying therapy for Alzheimer’s, and the first such therapy to come under FDA review. Disease-modifying therapies are those capable of slowing ...

Namenda (memantine) is an approved medicine for the treatment of moderate to severe Alzheimer’s disease. When nerve cells are damaged, it is believed that some start to release excess glutamate, ...

Alliance to advocate for specific funding into ApoE4 -related research Alzheimer’s disease is the most common cause of dementia, a group of cognitive symptoms that include memory loss, confusion, and ...

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

Evidence suggests that lithium can help treat and even prevent Alzheimer’s. Studies in an Alzheimer’s mouse model showed that treatment with AL001 prevented cognitive impairment, depression, and ...

The global Phase 2b/3 trial, called Anavex 2-73-AD-004 (NCT03790709), enrolled 509 people, ages 60-85, with mild cognitive impairments or mild dementia due to Alzheimer’s. The participants were ...

A second phase of this study will include biobank data from some 1,000 additional patients in Europe and the U.S, and it should be complete in the coming months, Diadem stated in the release. The test ...